M 8891

Drug Profile

M 8891

Alternative Names: M-8891

Latest Information Update: 17 May 2017

Price : $50

At a glance

  • Originator EMD Serono
  • Developer EMD Serono; Merck KGaA
  • Class Antineoplastics
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 08 May 2017 EMD Serono and Merck plan a phase I trial for Solid tumours (Monotherapy, Late-stage disease) in USA (PO) (NCT03138538)
  • 08 May 2017 Preclinical trials in Solid tumours in USA (PO) (NCT03138538)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top